Label-free quantitative mass spectrometry reveals novel pathways involved in LL-37 expression

Journal of Innate Immunity

Volumn 6, Issue 3, 2014, Pages 365-376

  Cederlund, Andreas ^a   Nylén, Frank ^a   Miraglia, Erica ^a   Bergman, Peter ^a,b   Gudmundsson, Gudmundur H ^c   Agerberth, Birgitta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Antimicrobial peptides; Host defense; LL 37; Pathway analysis; Proteomics

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLIC AMP; CYCLOOXYGENASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ICOSANOID; LACTOSE; LIOTHYRONINE; PHOSPHOLIPASE A2; RETINOID X RECEPTOR; THYROID HORMONE RECEPTOR; THYROXINE; ANTIMICROBIAL CATIONIC PEPTIDE; ARYLBUTYRIC ACID DERIVATIVE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; RECEPTOR; STEROID; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENYLBUTYRATE; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CELL STRAIN HT29; COLON MUCOSA; CONTROLLED STUDY; EPITHELIUM CELL; GENE; GENE CONTROL; INCUBATION TIME; LUCIFERASE ASSAY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STEROIDOGENESIS; BIOLOGY; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE MUCOSA; METABOLISM; PROTEOMICS; GENE INDUCTION; LABEL FREE QUANTIFICATION MASS SPECTROMETRY; REGULATORY MECHANISM;

ANTIMICROBIAL CATIONIC PEPTIDES; COMPUTATIONAL BIOLOGY; DRUG SYNERGISM; GENE EXPRESSION REGULATION; HT29 CELLS; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA; LACTOSE; MASS SPECTROMETRY; PHENYLBUTYRATES; PROTEOMICS; RECEPTORS, EICOSANOID; RECEPTORS, THYROID HORMONE; RETINOID X RECEPTORS; SIGNAL TRANSDUCTION; STEROIDS; THYROXINE; TRIIODOTHYRONINE;

EID: 84897429520     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000355931     Document Type: Article

References (40)

1. Netea MG, Wijmenga C, O'Neill LA: Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 2012; 13: 535-542.
2. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Teggatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA: Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11: 76-83.
3. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE: Impact of ll-37 on anti-infective immunity. J Leukoc Biol 2005; 77: 451-459.
4. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-Backdahl M: The cathelicidin anti-microbial peptide ll- 37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379-389.
5. van der Does AM, Bergman P, Agerberth B, Lindbom L: Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. J Leukocyte Biol 2012; 92: 735-742.
6. da Silva FP, Machado MCC: Antimicrobial peptides: clinical relevance and therapeutic implications. Peptides 2012; 36: 308-314.
7. Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, Nasirul Islam KM, Gudmundsson GH, Andersson J, Agerberth B: Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci USA 2006; 103: 9178-9183.
8. Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, Andersson J, Bergman P, Gudmundsson GH, Agerberth B, Raqib R: Phenylbutyrate counteracts shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One 2011; 6:e20637.
9. Liu PT, Stenger S, Tang DH, Modlin RL: Cutting edge: vitamin D-mediated human antimicrobial activity against mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-2063.
10. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA, Eldridge SM, Griffiths CJ: High-dose vitamin D(3) during intensivephase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-250.
11. Cederlund A, Kai-Larsen Y, Printz G, Yoshio H, Alvelius G, Lagercrantz H, Stromberg R, Jornvall H, Gudmundsson GH, Agerberth B: Lactose in human breast milk an inducer of innate immunity with implications for a role in intestinal homeostasis. PLoS One 2013; 8:e53876.
12. Termen S, Tollin M, Rodriguez E, Sveinsdottir SH, Johannesson B, Cederlund A, Sjovall J, Agerberth B, Gudmundsson GH: Pu.1 and bacterial metabolites regulate the human gene camp encoding antimicrobial peptide LL-37 in colon epithelial cells. Mol Immunol 2008; 45: 3947-3955.
13. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH: Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-2912.
14. Verbeek W, Lekstrom-Himes J, Park DJ, Dang PM, Vuong PT, Kawano S, Babior BM, Xanthopoulos K, Koeffler HP: Myeloid transcription factor C/EBPepsilon is involved in the positive regulation of lactoferrin gene expression in neutrophils. Blood 1999; 94: 3141-3150.
15. Nylen F, Miraglia E, Cederlund A, Ottosson H, Stromberg R, Gudmundsson GH, Agerberth B: Boosting innate immunity: development and validation of a cell-based screening assay to identify LL-37 inducers. Innate Immun 2013, E-pub ahead of print.
16. Cederlund A, Agerberth B, Bergman P: Specificity in killing pathogens is mediated by distinct repertoires of human neutrophil peptides. J Innate Immun 2010; 2: 508-521.
17. Lyutvinskiy Y, Yang H, Rutishauser D, Zubarev RA: In silico instrumental response correction improves precision of label-free proteomics and accuracy of proteomicsbased predictive models. Mol Cell Proteomics 2013; 12: 2324-2331.
18. Rajagopalan D, Agarwal P: Inferring pathways from gene lists using a literature-derived network of biological relationships. Bioinformatics 2005; 21: 788-793.
19. De Vito P, Incerpi S, Pedersen JZ, Luly P, Davis FB, Davis PJ: Thyroid hormones as modulators of immune activities at the cellular level. Thyroid 2011; 21: 879-890.
20. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-1875.
21. Lio YC, Reynolds LJ, Balsinde J, Dennis EA: Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta 1996; 1302: 55-60.
22. Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K: Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol 2003; 43: 573-585.
23. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 282-284.
24. Wright JM, Zeitlin PL, Cebotaru L, Guggino SE, Guggino WB: Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics 2004; 16: 204-211.
25. EMBL-EBI: Rex - retrieval of experiments 2686, 2012, 2012.
26. Luthje P, Brauner H, Ramos NL, Ovregaard A, Glaser R, Hirschberg AL, Aspenstrom P, Brauner A: Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013; 5: 190ra180.
27. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD: Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995; 123: 572-583.
28. Sandler B, Webb P, Apriletti JW, Huber BR, Togashi M, Cunha Lima ST, Juric S, Nilsson S, Wagner R, Fletterick RJ, Baxter JD: Thyroxine- thyroid hormone receptor interactions. J Biol Chem 2004; 279: 55801-55808.
29. Lee JK, Gordon PR, Stall GM, Gilchrest BA, Kaplan MM: Phenolic and tyrosyl ring iodothyronine deiodination by the caco-2 human colon carcinoma cell line. Metabolism 1989; 38: 1154-1161.
30. Velasco LF, Togashi M, Walfish PG, Pessanha RP, Moura FN, Barra GB, Nguyen P, Rebong R, Yuan C, Simeoni LA, Ribeiro RC, Baxter JD, Webb P, Neves FA: Thyroid hormone response element organization dictates the composition of active receptor. J Biol Chem 2007; 282: 12458-12466.
31. Meng S, Wu JT, Archer SY, Hodin RA: Shortchain fatty acids and thyroid hormone interact in regulating enterocyte gene transcription. Surgery 1999; 126: 293-298.
32. Tanaka Y, Bush KK, Klauck TM, Higgins PJ: Enhancement of butyrate-induced differentiation of HT-29 human colon carcinoma cells by 1,25-dihydroxyvitamin D3. Biochem Pharmacol 1989; 38: 3859-3865.
33. Lu X, Walker T, MacManus JP, Seligy VL: Differentiation of HT-29 human colonic adenocarcinoma cells correlates with increased expression of mitochondrial RNA: effects of trehalose on cell growth and maturation. Cancer Res 1992; 52: 3718-3725.
34. Schott J, Stoecklin G: Networks controlling mRNA decay in the immune system. Wiley Interdiscip Rev RNA 2010; 1: 432-456.
35. Li D, Yamada T, Wang F, Vulin AI, Samuels HH: Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/ RXR heterodimer. J Biol Chem 2004; 279: 7427-7437.
36. Stehlin-Gaon C, Willmann D, Zeyer D, Sanglier S, Van Dorsselaer A, Renaud JP, Moras D, Schule R: All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta. Nat Struct Biol 2003; 10: 820-825.
37. Wan M, Sabirsh A, Wetterholm A, Agerberth B, Haeggstrom JZ: Leukotriene b4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. FASEB J 2007; 21: 2897-2905.
38. Grosch S, Maier TJ, Schiffmann S, Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-747.
39. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou- Lin J, Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001; 91: 894-899.
40. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16: 624-629.